Wave Life Sciences Ltd. Statistics
Share Statistics
Wave Life Sciences Ltd. has 152.52M shares outstanding. The number of shares has increased by 7.48% in one year.
| Shares Outstanding | 152.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 4.55% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 118.14M |
| Failed to Deliver (FTD) Shares | 81 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 6.82M, so 4.47% of the outstanding shares have been sold short.
| Short Interest | 6.82M |
| Short % of Shares Out | 4.47% |
| Short % of Float | 5.77% |
| Short Ratio (days to cover) | 3.38 |
Valuation Ratios
The PE ratio is -9.32 and the forward PE ratio is -16.28.
| PE Ratio | -9.32 |
| Forward PE | -16.28 |
| PS Ratio | 4.73 |
| Forward PS | 33 |
| PB Ratio | 11.28 |
| P/FCF Ratio | -26.08 |
| PEG Ratio | n/a |
Enterprise Valuation
Wave Life Sciences Ltd. has an Enterprise Value (EV) of 367.56M.
| EV / Earnings | -6.39 |
| EV / Sales | 3.24 |
| EV / EBITDA | -6.25 |
| EV / EBIT | -5.41 |
| EV / FCF | -17.89 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.14.
| Current Ratio | 1.26 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.14 |
| Total Debt / Capitalization | 12.38 |
| Cash Flow / Debt | -2.89 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.21% and return on capital (ROIC) is -84.4%.
| Return on Equity (ROE) | -1.21% |
| Return on Assets (ROA) | -0.21% |
| Return on Capital (ROIC) | -84.4% |
| Revenue Per Employee | 425.96K |
| Profits Per Employee | -216.21K |
| Employee Count | 266 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -677.00K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 204.54% in the last 52 weeks. The beta is -1.21, so Wave Life Sciences Ltd.'s price volatility has been lower than the market average.
| Beta | -1.21 |
| 52-Week Price Change | 204.54% |
| 50-Day Moving Average | 13.57 |
| 200-Day Moving Average | 7.82 |
| Relative Strength Index (RSI) | 46.03 |
| Average Volume (20 Days) | 1.94M |
Income Statement
In the last 12 months, Wave Life Sciences Ltd. had revenue of $113.31M and earned -$57.51M in profits. Earnings per share was $-0.54.
| Revenue | 113.31M |
| Gross Profit | 104.10M |
| Operating Income | -68.00M |
| Net Income | -57.51M |
| EBITDA | -58.79M |
| EBIT | -68.00M |
| Earnings Per Share (EPS) | -0.54 |
Balance Sheet
The company has $200.35M in cash and $32.12M in debt, giving a net cash position of $168.23M.
| Cash & Cash Equivalents | 200.35M |
| Total Debt | 32.12M |
| Net Cash | 168.23M |
| Retained Earnings | -1.02B |
| Total Assets | 358.50M |
| Working Capital | 153.79M |
Cash Flow
In the last 12 months, operating cash flow was -$19.43M and capital expenditures -$1.11M, giving a free cash flow of -$20.55M.
| Operating Cash Flow | -19.43M |
| Capital Expenditures | -1.11M |
| Free Cash Flow | -20.55M |
| FCF Per Share | -0.19 |
Margins
Gross margin is 91.88%, with operating and profit margins of -60.01% and -50.76%.
| Gross Margin | 91.88% |
| Operating Margin | -60.01% |
| Pretax Margin | -51.36% |
| Profit Margin | -50.76% |
| EBITDA Margin | -51.89% |
| EBIT Margin | -60.01% |
| FCF Margin | -18.13% |
Dividends & Yields
WVE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.02% |
| FCF Yield | -1% |
Analyst Forecast
The average price target for WVE is $22, which is 63.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $22 |
| Price Target Difference | 63.8% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 0.61 |
| Piotroski F-Score | 3 |